XML 16 R5.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Service Receivable
Accumulated Deficit
Balance, beginning (in shares) at Dec. 31, 2017   60,600 733,217      
Balance, beginning at Dec. 31, 2017 $ 6,506,107 $ 60 $ 5,279 $ 179,546,954   $ (173,046,186)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 1,406,131     1,406,131    
Issuance of common stock upon exercise of warrants (in shares)     71,347      
Issuance of common stock upon exercise of warrants 1,449,167   $ 514 1,448,653    
Issuance of common stock upon vesting of restricted stock units (in shares)     12,567      
Issuance of common stock upon vesting of restricted stock units     $ 90 (90)    
Preferred stock dividend payable on Series A Convertible Preferred Stock (6,060)         (6,060)
Net loss (4,786,177)         (4,786,177)
Cumulative adjustment upon adoption of ASC 606 109,922         109,922
Balance, ending (in shares) at Mar. 31, 2018   60,600 817,131      
Balance, ending at Mar. 31, 2018 4,679,090 $ 60 $ 5,883 182,401,648   (177,728,501)
Balance, beginning (in shares) at Dec. 31, 2017   60,600 733,217      
Balance, beginning at Dec. 31, 2017 6,506,107 $ 60 $ 5,279 179,546,954   (173,046,186)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Release of clinical trial funding commitment 0          
Net loss (8,533,132)          
Balance, ending (in shares) at Jun. 30, 2018   66,250 2,884,168      
Balance, ending at Jun. 30, 2018 17,477,162 $ 66 $ 7,173 201,720,972   (184,251,049)
Balance, beginning (in shares) at Mar. 31, 2018   60,600 817,131      
Balance, beginning at Mar. 31, 2018 4,679,090 $ 60 $ 5,883 182,401,648   (177,728,501)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 221,300     221,300    
Issuance of common stock upon exercise of warrants (in shares)     7,570      
Issuance of common stock upon exercise of warrants 163,500   $ 55 163,445    
Preferred stock dividend payable on Series A Convertible Preferred Stock (6,060)         (6,060)
Issuance of common stock for share rounding as a result of reverse stock split (in shares)     1,134      
Net loss (3,746,955)         (3,746,955)
Sale of common stock and warrants, net of expenses (in shares)     1,523,333      
Sale of common stock and warrants, net of expenses 11,779,525   $ 914 11,778,611    
Issuance of common stock upon conversion of Series C Convertible Preferred Stock (in shares)   (3,210) 535,000      
Issuance of common stock upon conversion of Series C Convertible Preferred Stock   $ (3) $ 321 (318)    
Sale of Series B Convertible Preferred Stock, net of expenses (in shares)   8,860        
Sale of Series B Convertible Preferred Stock, net of expenses 4,386,762 $ 9   4,386,753    
Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance       2,769,533   (2,769,533)
Balance, ending (in shares) at Jun. 30, 2018   66,250 2,884,168      
Balance, ending at Jun. 30, 2018 17,477,162 $ 66 $ 7,173 201,720,972   (184,251,049)
Balance, beginning (in shares) at Dec. 31, 2018   60,600 3,831,879      
Balance, beginning at Dec. 31, 2018 10,084,192 $ 60 $ 7,742 202,267,605 $ 0 (192,191,215)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 200,067     200,067    
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses of $40,000 (in shares)   200,000 183,334      
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount of $40,000 and $235,640, respectively (40,000) $ 200 $ 110 1,634,690 (1,675,000)  
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance       268,269   (268,269)
Issuance of common stock upon exercise of warrants (in shares)     497,313      
Issuance of common stock upon exercise of warrants 3,282,266   $ 50 3,282,216    
Issuance of common stock upon vesting of restricted stock units (in shares)     6,362      
Issuance of common stock upon vesting of restricted stock units     $ 4 (4)    
Preferred stock dividend payable on Series A Convertible Preferred Stock (6,060)         (6,060)
Issuance of common stock for share rounding as a result of reverse stock split (in shares)     6,466      
Release of clinical trial funding commitment 70,487       70,487  
Net loss (3,904,771)         (3,904,771)
Balance, ending (in shares) at Mar. 31, 2019   260,600 4,525,354      
Balance, ending at Mar. 31, 2019 9,686,181 $ 260 $ 7,906 207,652,843 (1,604,513) (196,370,315)
Balance, beginning (in shares) at Dec. 31, 2018   60,600 3,831,879      
Balance, beginning at Dec. 31, 2018 10,084,192 $ 60 $ 7,742 202,267,605 0 (192,191,215)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of warrants (in shares)     497,313      
Issuance of common stock for share rounding as a result of reverse stock split (in shares)     6,466      
Release of clinical trial funding commitment (310,766)          
Net loss (8,030,074)          
Sale of Series B Convertible Preferred Stock, net of expenses (in shares)     1,609,511      
Balance, ending (in shares) at Jun. 30, 2019   60,600 5,441,390      
Balance, ending at Jun. 30, 2019 8,848,235 $ 60 $ 7,997 210,706,090 (1,364,234) (200,501,678)
Balance, beginning (in shares) at Mar. 31, 2019   260,600 4,525,354      
Balance, beginning at Mar. 31, 2019 9,686,181 $ 260 $ 7,906 207,652,843 (1,604,513) (196,370,315)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 148,834     148,834    
Issuance of common stock upon exercise of warrants (in shares)     156,353      
Issuance of common stock upon exercise of warrants 1,564   $ 16 1,548    
Issuance of common stock upon vesting of restricted stock units (in shares)     4,433      
Issuance of common stock upon vesting of restricted stock units     $ 0 0    
Preferred stock dividend payable on Series A Convertible Preferred Stock (6,060)         (6,060)
Release of clinical trial funding commitment 240,279       240,279  
Net loss (4,125,303)         (4,125,303)
Sale of common stock and warrants, net of expenses (in shares)     421,917      
Sale of common stock and warrants, net of expenses 2,902,740   $ 42 2,902,698    
Issuance of common stock upon conversion of Series C Convertible Preferred Stock (in shares)   (200,000) 333,333      
Issuance of common stock upon conversion of Series C Convertible Preferred Stock   $ (200) $ 33 167    
Balance, ending (in shares) at Jun. 30, 2019   60,600 5,441,390      
Balance, ending at Jun. 30, 2019 $ 8,848,235 $ 60 $ 7,997 $ 210,706,090 $ (1,364,234) $ (200,501,678)